SELECTION Positive For Gilead/Galapagos’s Filgotinib In UC But Will It Be Enough To Compete?
Ulcerative Colitis Market Is Crowded
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.
You may also be interested in...
Galapagos and Gilead's JAK inhibitor has been approved for rheumatoid arthritis in the second and third biggest pharma markets, softening the blow somewhat of rejection from the US FDA in the biggest market last month.
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.